All systems operational
Q2 2021

Incidence, etiology, and course of hypercalcemia-induced AKI in a tertiary care center from northern India

Nucksheeba Aziz Bhat · Farhat Mustafa · Rayees Yousuf Sheikh · Imtiyaz Wani
10.1186/s43162-021-00067-8 381 Views 13 Citations
13
Citations
381
Views
Abstract

Abstract
Background
Hypercalcemia is known to cause acute kidney injury (AKI). Literature related to hypercalcemic AKI is predominantly in the form of case reports and case series. The purpose of this study is to find the incidence, etiology, and course of hypercalcemia-induced AKI in a non-critical care setting. To our knowledge, this is the first study done to look for the incidence, etiology, and course of hypercalcemia-induced AKI in a non-critical care setting. This is a prospective observational study conducted in the Department of Medicine in a tertiary care center from Jammu and Kashmir, India, from June 2010 to June 2012. Patients admitted with hypercalcemia were assessed for AKI and evaluated and treated for hypercalcemia. Renal function was monitored during hospitalization and at 1 month of discharge. AKI and hypercalcemia were arbitrarily defined as serum creatinine > 1.5 mg/dl and corrected serum calcium of ≥ 11.5 mg/dl (as per reference hospital lab), respectively.

Results
Thirty patients are included. Hyperparathyroidism and multiple myeloma accounted for 13(43.3%) and 10 (33.3%) cases, respectively. Mean ±SD corrected serum calcium at diagnosis and after treatment at 1 month was 13.56 ± 1.86 mg/dl and 9.49±1.35 mg/dl, respectively; p < 0.001. Mean ±SD serum creatinine at baseline and after treatment of hypercalcemia was 2.87 ±1.68 mg/dl and 1.49±1.34 mg/dl, respectively; p < 0.001. Twenty-three (76.7%) patients had AKI. AKI recovered after treating hypercalcemia in 25 (83.3 %) patients. Mean ± SD days taken for the decrease in serum creatinine to ≤ 1.5 mg/dl was 8.28 ± 4.17 days. Mean ± SD serum creatinine after treatment of hypercalcemia in hyperparathyroidism group versus non-parathyroid group was 0.97 ± 0.35 mg/dl and 1.88 ±1.67 mg/dl, respectively; p value 0.009.

Conclusions
Hypercalcemia is commonly associated with AKI. Primary hyperparathyroidism and multiple myeloma account for the majority of the cases. Hypercalcemic AKI with primary hyperparathyroidism is less common and the outcome is better, as compared to non-hyperparathyroidism-related causes. AKI is reversible in most cases.

Cite this Article (APA)
Nucksheeba, A. B., Farhat, M., Rayees, Y. S., Imtiyaz, W. (2021). Incidence, etiology, and course of hypercalcemia-induced AKI in a tertiary care center from northern India. The Egyptian Journal of Internal Medicine. https://doi.org/10.1186/s43162-021-00067-8
Related Papers
Antiangiogenic role of natural flavonoids and their molecular mechanism: an update
Gowtham Kumar Subbaraj; Yasam Santhosh Kumar; Langeswaran Kulanthaivel · 2021
34
cites
391
Bridging autoinflammatory and autoimmune diseases
Emad M. El-Shebiny; Enas S. Zahran; Sabry A. Shoeib; Eman S. Habib · 2021
30
cites
390
Factors affecting glycemic control among Egyptian people with diabetes attending primary health care…
Mai Mohamed Azzam; Adel Alwehedy Ibrahim; Mohammed I. Abd El-Ghany · 2021
27
cites
394
A narrative review of pox: smallpox vs monkeypox
Samiksha Jayswal; Jagdish Kakadiya · 2022
23
cites
390
Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically venti…
Mohammed Abdel Monem Saeed; Alaa Hussein Mohamed; Ahmed Hassan Owaynat · 2022
20
cites
394
Access
View Full Text via DOI
Published in
ISSN 1110-7782
Quartile Q2
AMS Score 94
Field Medicine & Health Sciences
Publisher Springer (Biomed Central Ltd.)
Country 🇪🇬 Egypt
View Journal Profile →
Authors
Publication Details
Year 2021
Language English
Added 14 Aug 2026